Posted by Michael Wonder on 30 Oct 2018
U.S. FDA approves Invokana (canagliflozin) to reduce the risk of heart attack, stroke or cardiovascular death in adults with type 2 diabetes and established cardiovascular disease
30 October 2018 - Invokana is now the only oral diabetes treatment approved to reduce the risk of these cardiovascular events.
Janssen announced today that the U.S. FDA has approved Invokana (canagliflozin) to reduce the risk of major adverse cardiovascular (CV) events, including heart attack, stroke or death due to a cardiovascular cause in adults with type 2 diabetes (T2D) who have established CV disease.
The CANVAS (CANagliflozin cardioVascular Assessment Study) Program evaluated the effect of Invokana on CV risk in a broad population of more than 10,000 adults with T2D who had established CV disease (65%) or were at risk for cardiovascular disease with two or more risk factors (35%).
